3Helix, Inc. — SEC Form D Filing

3Helix, Inc. filed an SEC Form D on September 18, 2026, reporting $7.84M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 18, 2026
Amount reported
$7.84M
Industry
Biotechnology
Website
https://www.3helix.com/pages/welcome

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Collagen damage is a hidden driver of disease, disrupting normal cell communication, tissue structure, and repair processes, which leads to inflammation, tissue breakdown, and poor health outcomes.

Solution

3Helix develops bioACTIVE Collagen Hybridizing Peptides (CHPs) that selectively target damaged and remodeling collagen, promoting a localized, anti-inflammatory response to address the underlying cause of tissue damage.

Verdict

Investors backed a specialized biotech platform targeting a fundamental biological process rather than a specific disease indication. This cleared because the underlying science promised broad applicability across multiple therapeutic areas, not because the company had proven clinical efficacy in a single market. They were implicitly betting on the modularity and precise targeting capabilities of the Collagen Hybridizing Peptides (CHPs) to unlock diverse and high-value applications. What limited upside was the inherent long development cycles and capital intensity associated with translating novel peptide technologies into approved therapeutic products, requiring sustained funding beyond this initial raise.

Source: SEC EDGAR Form D filing